GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Pretax Margin %

AVTX (Avalo Therapeutics) Pretax Margin % : -18,346.35% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Avalo Therapeutics's Pre-Tax Income for the three months ended in Dec. 2024 was $-35.23 Mil. Avalo Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.19 Mil. Therefore, Avalo Therapeutics's pretax margin for the quarter that ended in Dec. 2024 was -18,346.35%.

The historical rank and industry rank for Avalo Therapeutics's Pretax Margin % or its related term are showing as below:

AVTX' s Pretax Margin % Range Over the Past 10 Years
Min: -7939.91   Med: -1002.79   Max: 49.75
Current: -7939.91


AVTX's Pretax Margin % is ranked worse than
90.92% of 1002 companies
in the Biotechnology industry
Industry Median: -138.59 vs AVTX: -7939.91

Avalo Therapeutics Pretax Margin % Historical Data

The historical data trend for Avalo Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Pretax Margin % Chart

Avalo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,002.79 -1,566.23 -230.62 -1,638.77 -7,939.91

Avalo Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,432.05 - - 9,246.18 -18,346.35

Competitive Comparison of Avalo Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Avalo Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Pretax Margin % falls into.


;

Avalo Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Avalo Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-35.015/0.441
=-7,939.91 %

Avalo Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-35.225/0.192
=-18,346.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avalo Therapeutics  (NAS:AVTX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Avalo Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Executives
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd. 10 percent owner PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan officer: Interim CFO C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil officer: Chief Medical Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan director C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski officer: Chief Commercial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson director 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller director C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Schond L. Greenway officer: CFO & Treasurer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins officer: Chief Medical Officer 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr officer: Chief Commercial Officer C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022